Negative HIV test at screening
Negative serum pregnancy test at screening
A negative pregnancy test (if female)
Negative serum pregnancy test
Negative serum pregnancy test within  days prior to starting treatment
Female patients must have a negative pregnancy test
A negative serum pregnancy test
Have a negative result confirmed for a medically supervised urine (or serum) pregnancy test (with a sensitivity of at least  mIU/mL) - days prior to the first dose of IP. A second pregnancy test performed within  hours prior to the first dose of IP must also be confirmed to be negative prior to IP administration.
Pregnancy or lactation at the time of randomization or intention to become pregnant during the study. (Note: Negative serum pregnancy test must be obtained within  days prior to randomization).
And have a negative serum pregnancy test at screening
Negative serum pregnancy test
In female, a negative pregnancy test if experiencing menstrual periods.
Female subjects with reproductive potential must agree to undergo a medically supervised pregnancy test prior to starting study drug. The first pregnancy test will be performed at screening (within  days prior to first study drug administration). A pregnancy test should also be performed on the day of the first study drug administration and confirmed negative prior to dosing as well as before dosing on Day  of all subsequent cycles
Negative serum pregnancy test at screening
Pregnant or need to breast feed during the study period (negative serum pregnancy test required)
have a negative serum pregnancy test at the time of enrollment,
Negative serum pregnancy test.
Has a negative serum pregnancy test within  days prior to starting treatment.
And have a negative serum pregnancy test ?  days of cycle , day  (CD)
For WoCBP* negative serum pregnancy test within  days of enrollment.
In female, a negative pregnancy test if experiencing menstrual periods
Negative serum pregnancy test
PRIOR TO LYMPHODEPLETION: For WOCBP negative serum pregnancy test within  hours prior to lymphodepletion
have a negative serum pregnancy test at screening and before Betalutin injection
A negative Hepatitis B test (HBsAg and anti-HBc) and negative HIV test during screening
Women who are not postmenopausal or have not undergone hysterectomy must have a documented negative serum pregnancy test per standard MCC-VCUHS BMT Program guidelines
Negative serum pregnancy test
Negative serum pregnancy test
Negative pregnancy test
For females of childbearing age, they may participate it they: a. have a negative serum or urine pregnancy test within  to  days of enrolling (a second pregnancy test will be performed within  hours (hrs) of starting therapy and both negative pregnancy tests will be required for starting therapy); b. agree to either abstinence or  effective contraceptive methods throughout the treatment period and up to  days after discontinuing treatment
Negative pregnancy test at the time of SRS in any patient who could be pregnant
Pregnancy or breastfeeding; female patients who are post-menarchal must have a documented negative pregnancy test
Women of child-bearing potential must have a negative serum pregnancy test at screening; in addition to having a negative pregnancy test confirmed at screening, all female participants of childbearing potential must have a negative pregnancy test confirmed within  hours prior to dosing with the study drug
Negative pregnancy test, if applicable
Negative pregnancy test
WOCBP must have a negative pregnancy test within  hours prior to Study Day .
Female patients with an intact uterus (unless amenorrheic for the last  months) must have a negative serum pregnancy test within  hours prior to administration of any treatment
Negative pregnancy test
A negative pregnancy test (if female).
Have  negative pregnancy tests as verified by the Investigator prior to starting any IP therapy: serum pregnancy test at screening and negative serum or urine pregnancy test (Investigator's discretion) within  hours prior to starting treatment with IP (Cycle , Day ). They must agree to ongoing pregnancy testing during the course of the study (before beginning each subsequent cycle of treatment), and after the last dose of any IP. This applies even if the subject practices complete abstinence[] from heterosexual contact.
Agree to have a medically supervised serum pregnancy test with sensitivity of at least  mIU/mL obtained at Screening. A serum pregnancy test is to be performed within  hours prior to Day  of starting study therapy on Cycle  Day -, and within  hours prior to Day  of every subsequent cycle, and at the Treatment Discontinuation Visit. The subject may not receive IP until the Investigator has verified that the result of the pregnancy test is negative.
Negative serum pregnancy test at screening (sensitivity of at least  mIU/mL); (Note that the screening serum pregnancy test can be used as the test prior to starting IP in the pharmacokinetics phase if it is performed within the -hour timeframe), and
Negative serum pregnancy test
WOCBP must have a negative serum pregnancy test within  days prior to the first dose of ipilimumab/nivolumab
Documentation of negative pregnancy test.
Must have a negative serum pregnancy test
Negative pregnancy test at screening
Negative serum pregnancy test; if, on cycle  day , greater than  hours has elapsed since the last negative result, a serum pregnancy test must be repeated and be negative on cycle  day  (CD) for the patient to remain eligible
Negative serum pregnancy test at screening.
FCBP must have  negative pregnancy tests (sensitivity of at least  mIU/mL) prior to initiating lenalidomide; the first pregnancy test must be performed within - days before day  cycle  and the second pregnancy test must be performed within  hours of day  cycle ; the subject may not receive lenalidomide until the treating investigator has verified that the results of these pregnancy tests are negative, and must agree to ongoing pregnancy tests; for patients already on Revlimid, continuation of current testing schedule is permitted as long as it is not interrupted during the transition to CRd therapy
Negative pregnancy test for WOCBP
Patients of childbearing age must have a negative pregnancy test
A FCBP must have two negative pregnancy tests (sensitivity of at least  mIU/mL) prior to starting study drug; the first pregnancy test must be performed within - days prior to the start of study drug and the second pregnancy test must be performed within  hours prior to prescribing the study drug; the subject may not receive study drug until the investigator has verified that the results of these pregnancy tests are negative
Negative pregnancy test.
Negative pregnancy test if applicable
And have a negative blood pregnancy test at the time of screening
And have a negative serum pregnancy test at screening
Negative serum test for pregnancy in premenopausal women
Negative serum pregnancy test.
Women must have a negative serum pregnancy test
WOCBP must have a negative serum pregnancy test within  days prior to receiving investigational product and a negative urine pregnancy test on Day  of each Cycle;
A negative serum pregnancy test (if female)
Negative pregnancy test
Negative pregnancy test
Negative pregnancy test
Negative pregnancy test
Negative pregnancy test
negative serum pregnancy test
Negative pregnancy test
Must have a negative serum pregnancy test at screening and day -, and
Pregnancy or breastfeeding - menstruating females must have a negative pregnancy test prior to study enrollment and agree to repeat pregnancy testing and contraception use per protocol
Negative pregnancy test at study registration
Negative pregnancy test
Negative pregnancy test
They are not pregnant (i.e., female patients must have a negative serum pregnancy test at screening);
Pregnancy, confirmed by a negative pregnancy test within  days of study enrollment
All WOCBP MUST have a negative pregnancy test prior to first receiving study medication
Negative pregnancy test =<  days prior to randomization
Have two negative pregnancy tests as verified by the investigator prior to starting any IP therapy: serum pregnancy test at screening and negative serum or urine pregnancy test (investigator's discretion) within  hours prior to starting treatment with IP (Cycle , Day ). They must agree to ongoing pregnancy testing during the course of the study (before beginning each subsequent cycle of treatment), and after the last dose of any IP. This applies even if the subject practices complete abstinence from heterosexual contact.
has a negative pregnancy test on the day of vaccination, and
has a negative pregnancy test on the day of vaccination, and
Pregnancy or nursing patients will be excluded from the study; a pregnancy test will be done prior to the MR examination for postmenarchal teenage girls, in whom pregnancy may be possible; only patients with a negative pregnancy test will be included in the study
Pregnancy or nursing patients will be excluded from the study; a pregnancy test will be done prior to the MR examination for postmenarchal teenage girls, in whom pregnancy may be possible; only patients with a negative pregnancy test will be included in the study
Determination of pregnancy status: Female patients who are not postmenopausal or surgically sterile will undergo a serum pregnancy test prior to each set of [F]FLT and [F] Fluciclovine PET scans; a negative test will be necessary for such patients to undergo research PET imaging
In female patients, negative pregnancy test with no plans to become pregnant during the duration of the study
Determination of pregnancy status: female patients that are not postmenopausal or surgically sterile will undergo a serum pregnancy test prior to each set of multi-tracer PET scans; a negative test will be necessary for such patients to undergo research PET imaging
Negative serum pregnancy test
Female patients who are not postmenopausal or surgically sterile will undergo a serum pregnancy test prior to baseline and the subsequent set of multi-tracer PET scans; the serum pregnancy test must be performed within  hours prior to research PET imaging; a negative test will be necessary for such patients to undergo research PET imaging
Determination of pregnancy status: female patients who are not postmenopausal or surgically sterile will undergo a serum pregnancy test prior to baseline and the subsequent set of multi-tracer PET scans; the serum pregnancy test must be performed within  hours prior to research PET imaging; a negative test will be necessary for such patients to undergo research PET imaging
